Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice

Ziconotide is a selective and potent blocker of N‐type voltage‐gated calcium channels. It was approved by the Food and Drug Administration in 2004 and by the European Medicines Agency in 2005 for the treatment of severe chronic pain in patients needing intrathecal analgesia ( ITA ). The aim of this paper is to provide a practitioner‐oriented, educational, narrative, up‐to‐date review on the use of ziconotide in clinical pain medicine. Of special...